NCT07382674 Zesty Exercise System for Therapeutic Engagement
| NCT ID | NCT07382674 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 46 participants |
| Start Date | 2026-03-16 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 46 participants in total. It began in 2026-03-16 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate exercise delivered through the Zesty Exercise System for Therapeutic Engagement (ZEST-E) for people with Parkinson's disease when sessions are monitored either in person or remotely. Participants will complete robot-guided exercise three times per week for three weeks. The study will assess feasibility, retention, safety, acceptability, and tolerability of remotely monitored ZEST-E and will measure changes in functional performance using the Standing Forward Reach test and the 30-Second Chair Stand test. These outcomes reflect range of motion and lower-body strength targeted by the exercise program.
Eligibility Criteria
Inclusion Criteria: -Older adults with mild to moderate PD. Exclusion Criteria: * Acute medical illness requiring hospitalization; * Under 40 years old; * Uncontrolled congestive heart failure; * History of stroke in the past three years; * Inability to perform study procedures; * Medical or physical conditions that would preclude participation (e.g., severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renal failure, history of angina with activity); * On medications that could adversely affect cognition, e.g.: antipsychotics, opioids, stimulants, chemotherapy; * Psychotic disorders; * Confounding neurologic conditions (e.g., active central nervous system opportunistic infections, seizure disorders, head injury with loss of consciousness \>30 minutes, intracranial neoplasms, stroke with neurological or neuropsychiatric sequelae); * Substance Use Disorder, Major Depressive and Generalized Anxiety Disorders within six months of evaluation; * Hohn \& Yahr \> 3 * MoCA \<17
Contact & Investigator
Madeleine Hackney, PhD
PRINCIPAL INVESTIGATOR
Emory University
Frequently Asked Questions
Who can join the NCT07382674 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07382674 currently recruiting?
Yes, NCT07382674 is actively recruiting participants. Contact the research team at mehackn@emory.edu for enrollment information.
Where is the NCT07382674 trial being conducted?
This trial is being conducted at Atlanta, United States.
Who is sponsoring the NCT07382674 clinical trial?
NCT07382674 is sponsored by Emory University. The principal investigator is Madeleine Hackney, PhD at Emory University. The trial plans to enroll 46 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.